A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT03222609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis (MF)

Interventions

DRUG: Ruxolitinib
DRUG: Navitoclax

Sponsor

AbbVie